Lubner David Charles's Insider Trades & SAST Disclosures
Lubner David Charles's most recent trade in CARGO Therapeutics Inc was a trade of 23,742 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 4, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Lubner David Charles.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CARGO Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 23,742 | 23,742 | - | - | Stock Option (Right to Buy) | |
| Arcellx Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2024 | 8,011 | 8,011 | - | - | Stock Option (right to buy) | |
| Vor Biopharma Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Dyne Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 25,133 | 25,133 | - | - | Stock option (right to buy) | |
| POINT Biopharma Global Inc | David Charles Lubner | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Dec 2023 | 44,749 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Lubner David Charles | Director | 26 Dec 2023 | 35,400 | 3,600 | - | - | Common Stock | ||
| POINT Biopharma Global Inc | David Charles Lubner | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Dec 2023 | 25,614 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | David Lubner Charles | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Dec 2023 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | Lubner David Charles | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Dec 2023 | 3,600 | 0 | - | - | Common Stock | |
| Arcellx Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 11,459 | 11,459 | - | - | Stock Option (right to buy) | |
| POINT Biopharma Global Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 44,749 | 44,749 | - | - | Stock Option (Right to Buy) | |
| Vor Biopharma Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Dyne Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 24,900 | 24,900 | - | - | Stock Option (right to buy) | |
| POINT Biopharma Global Inc | David Charles Lubner | Director | Purchase of securities on an exchange or from another person at price $ 6.85 per share. | 23 Nov 2022 | 3,600 | 3,600 | - | 6.9 | 24,660 | Common Stock |
| Dyne Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2022 | 7,222 | 7,222 | - | - | Stock Option (right to buy) | |
| Vor Biopharma Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 16,911 | 16,911 | - | - | Stock Option (right to buy) | |
| Dyne Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2022 | 19,596 | 19,596 | - | - | Stock Option (right to buy) | |
| POINT Biopharma Global Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 25,614 | 25,614 | - | - | Stock Option (Right to Buy) | |
| Arcellx Inc | David Charles Lubner | Director | 08 Feb 2022 | 21,659 | 0 | - | - | Series C Preferred Stock | ||
| Arcellx Inc | David Charles Lubner | Director | 08 Feb 2022 | 21,659 | 21,659 | - | 0 | Common Stock | ||
| Arcellx Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2022 | 61,538 | 61,538 | - | - | Stock Option (right to buy) | |
| Disc Medicine Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2021 | 17,245 | 17,245 | - | - | Stock Option (Right to Buy) | |
| POINT Biopharma Global Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Dyne Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 19,596 | 19,596 | - | - | Stock Option (right to buy) | |
| Disc Medicine Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 58,855 | 58,855 | - | - | Stock Option (Right to Buy) | |
| Disc Medicine Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Vor Biopharma Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 16,900 | 16,900 | - | - | Stock Option (right to buy) | |
| Dyne Therapeutics Inc | David Charles Lubner | Director | 31 Jul 2020 | 177,872 | 0 | - | - | Series B Preferred Stock | ||
| Dyne Therapeutics Inc | David Charles Lubner | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 31 Jul 2020 | 177,872 | 177,872 | - | - | Series B Preferred Stock | |
| Dyne Therapeutics Inc | David Charles Lubner | Director | 31 Jul 2020 | 53,625 | 53,625 | - | - | Common Stock | ||
| Dyne Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2020 | 14,444 | 14,444 | - | - | Stock Option (right to buy) | |
| Dyne Therapeutics Inc | David Charles Lubner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2020 | 11,156 | 11,156 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges